In an interview with OncLive, Dr Toni Choueiri from Harvard Medical School, Dana-Farber Cancer Institute in America, discusses recent progress in renal cell carcinoma (RCC) and future research in this area.

Dr Choueiri talks about the breakthroughs in the treatment of patients with RCC over the last decade, such as checkpoint inhibitors, targeted agents, and combination regimens. He also mentions that although the outlook for RCC patients is bright, there remains the challenge of refining what is now a complex treatment landscape. In this respect, he talks about the pivotal CheckMate-214 trial comparing the nivolumab and ipilimumab combination versus sunitinib in patients with previously untreated RCC, which improved progression-free survival in patients with intermediate- and poor-risk RCC, but not favourable-risk RCC.

He also talks about biomarkers for RCC, which continue to be explored, especially inconsistency of PD-L1 expression in predicting immune response.

Read Dr Choueiri’s interview in OncLive here